Aruma Labs teams up with Applied Cannabis Research for endometriosis observational study – World News ReportPosted by On


Applied Cannabis Research, providing research expertise and services to medicinal cannabis companies

Australia’s leading contract research organization focused on medicinal cannabis treatments

200 women to take part to monitor the safety & efficacy of medical cannabis as a management option for refractory chronic pain, a common endometriosis symptom.

SYDNEY, NSW, AUSTRALIA, January 31, 2021 /EINPresswire.com/ — Applied Cannabis Research is pleased to announce Aruma Labs (Aruma) has joined Australia’s longest running observational study of medicinal cannabis products, the CA Clinics Observational Study (CACOS*), with a focus on collecting data from patients with endometriosis.

Endometriosis is a notoriously painful condition affecting more than 11% of Australian women, according to Endometriosis Australia. It is characterised by the presence of endometrial tissue, normally found inside the uterus, in other areas of the abdomen. The reduction in quality of life for women with endometriosis has been estimated at A$4 billion per annum (Ernst & Young (2019): The Cost of Endometriosis in Australia Report).

200 women will participate in the study to monitor the safety and efficacy of medicinal cannabis as an adjunct treatment and management option for refractory chronic pain, a common symptom of endometriosis.

KEY HIGHLIGHTS:
-200 Australian women will be recruited…

Original Author Link click here to read complete story..

Applied Cannabis Research, providing research expertise and services to medicinal cannabis companies

Australia’s leading contract research organization focused on medicinal cannabis treatments

200 women to take part to monitor the safety & efficacy of medical cannabis as a management option for refractory chronic pain, a common endometriosis symptom.

SYDNEY, NSW, AUSTRALIA, January 31, 2021 /EINPresswire.com/ — Applied Cannabis Research is pleased to announce Aruma Labs (Aruma) has joined Australia’s longest running observational study of medicinal cannabis products, the CA Clinics Observational Study (CACOS*), with a focus on collecting data from patients with endometriosis.

Endometriosis is a notoriously painful condition affecting more than 11% of Australian women, according to Endometriosis Australia. It is characterised by the presence of endometrial tissue, normally found inside the uterus, in other areas of the abdomen. The reduction in quality of life for women with endometriosis has been estimated at A$4 billion per annum (Ernst & Young (2019): The Cost of Endometriosis in Australia Report).

200 women will participate in the study to monitor the safety and efficacy of medicinal cannabis as an adjunct treatment and management option for refractory chronic pain, a common symptom of endometriosis.

KEY HIGHLIGHTS:
-200 Australian women will be recruited…



Source link

News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.